Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

11 Sep 2025 12:20

RNS Number : 0015Z
Genus PLC
11 September 2025
 

11 September 2025

 

Genus plc

 

Director/PDMR Shareholding

 

Genus plc (LSE: GNS) announces that on 10 September 2025, conditional share awards were granted under the Genus 2019 Performance Share Plan ('PSP') over ordinary shares in Genus to the Executive Directors and members of the Genus Executive Leadership Team ('GELT') as listed in table A below. In addition, following Genus's compulsory deferral requirements relating to the annual bonus earned by Executive Directors and GELT for the financial year ended 30 June 2025, share awards were granted over ordinary shares under the Genus 2019 Deferred Share Bonus Plan ('DSBP') as listed in table B below.

 

Details of the performance conditions that apply to the conditional share awards can be found in the Directors' Remuneration Report of the Genus 2025 Annual Report which will be published next month.

The price at which PSP and DSBP share awards have been granted was determined in accordance with the PSP and DSBP rules.

 

Genus further announces that:

· in accordance with the terms of joining contained in his employment contract, Andy Russell, Chief Financial Officer, was granted contingent rights over 9,014 ordinary shares in Genus under an individual award agreement with a normal vesting date of 10 September 2027;

· in accordance with the terms of joining contained in her employment contract, Lucie Grant, Group General Counsel and Company Secretary was granted contingent rights over 1,351 ordinary shares in Genus under an individual award agreement with a normal vesting date of 17 March 2027;

· Matt Culbertson, Chief Operating Officer PIC, was granted contingent rights over 12,610 ordinary shares in Genus under an individual award agreement with a normal vesting date of 10 September 2028; and

· Jim Low, Chief Operating Officer ABS, was granted contingent rights over 12,610 ordinary shares in Genus under an individual award agreement with a normal vesting date of 10 September 2028,

as listed in table C below.

 

Subject to the terms of the individual award agreements and continued service, the awards will vest on the normal vesting dates as specified above.

 

No consideration was paid for the grant of these awards and no consideration is due in connection with the vesting of these awards.

 

The below notifications, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, give further detail of the nil-cost option awards made on 10 September 2025.

 

For further information please contact:

 

Genus:

Vaughn Walton, Deputy Company Secretary Tel: +44 (0)1256 347100

 

Table A - GELT 2019 Performance Share Plan Options

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Jorgen Kokke

2. Andy Russell

3. Mark Birri

4. Matt Culbertson

5. Jim Low

6. Elena Rice

7. Angelle Rosata

8. Lucie Grant

2.

Reason for the notification

a.

Position/status

1. Chief Executive Officer

2. Chief Financial Officer

3. Chief Corporate Development Officer

4. Chief Operating Officer Genus PIC

5. Chief Operating Officer Genus ABS

6. Chief Scientific Officer

7. Group Human Resources Director

8. Group General Counsel & Company Secretary

b.

Initial notification

/Amendment

 

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Genus plc

b.

LEI

54930022EOITNKSIGH56

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 10p each.

 

 

GB0002074580

b.

Nature of the transaction

Award of shares granted under the PSP over ordinary shares in Genus.

 

c.

Price(s) and volume(s)

Numbers 1 to 8 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

 

Price(s)

 

Volume(s)

1. 0p

32,573

2. 0p

21,369

3. 0p

8,102

4. 0p

13,559

5. 0p

12,131

6. 0p

11,880

7. 0p

10,764

8. 0p

10,801

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

 

e.

Date of the transaction

2025-09-10

f.

Place of the transaction

Outside a trading venue.

 

 

Table B - GELT 2019 Deferred Share Bonus Plan Options

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Jorgen Kokke

2. Mark Birri

3. Matt Culbertson

4. Jim Low

5. Elena Rice

6. Angelle Rosata

7. Lucie Grant

2.

Reason for the notification

a.

Position/status

1. Chief Executive Officer

2. Chief Corporate Development Officer

3. Chief Operating Officer Genus PIC

4. Chief Operating Officer Genus ABS

5. Chief Scientific Officer

6. Group Human Resources Director

7. Group General Counsel & Company Secretary

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Genus plc

b.

LEI

54930022EOITNKSIGH56

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 10p each.

 

 

GB0002074580

b.

Nature of the transaction

Award of shares granted under the DSBP following the compulsory deferral of 33% and 25% of annual bonus for Executive Directors and members of GELT respectively in respect of bonuses earned in the financial year ended 30 June 2025.

 

c.

Price(s) and volume(s)

Numbers 1 to 7 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

 

Price(s)

 

Volume(s)

1. 0p

15,491

2. 0p

613

3. 0p

3,224

4. 0p

2,862

5. 0p

2,803

6. 0p

2,474

7. 0p

710

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

2025-09-10

 

f.

Place of the transaction

Outside a trading venue.

 

 

Table C - Restricted Stock Awards

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1. Andy Russell

2. Lucie Grant

3. Matt Culbertson

4. Jim Low

2.

Reason for the notification

a)

Position/status

1. Chief Financial Officer

2. Group General Counsel and Company Secretary

3. Chief Operating Officer Genus PIC

4. Chief Operating Officer Genus ABS

b)

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genus plc

b)

LEI

54930022EOITNKSIGH56

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 10p each.

 

 

GB0002074580

b)

Nature of the transaction

Grant of contingent rights over ordinary shares in Genus under individual award agreements

c)

Price(s) and volume(s)

Numbers 1 to 4 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

 

Price(s)

 

Volume(s)

1. 0p

9,014

2. 0p

1,351

3. 0p

12,610

4. 0p

12,610

5.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

6.

Date of the transaction

2025-09-10

 

7.

Place of the transaction

Outside a trading venue.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUAAARVBUKAAR
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.